These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34234609)

  • 21. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
    Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
    Richardson PG; Lee HC; Abdallah AO; Cohen AD; Kapoor P; Voorhees PM; Hoos A; Wang K; Baron J; Piontek T; Byrne J; Richmond S; Jewell RC; Opalinska J; Gupta I; Lonial S
    Blood Cancer J; 2020 Oct; 10(10):106. PubMed ID: 33097687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials.
    Tao Y; Zhou H; Niu T
    Front Pharmacol; 2021; 12():758992. PubMed ID: 34925019
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
    Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
    Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
    Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
    Popat R; Lonial S; Voorhees PM; Esposti SD; Gorsh B; Gupta I; Opalinska J; Sapra S; Piontek T; He Z; Kleinman D; Schaumberg D; Regnault A; Meunier J; Eliason L
    J Adv Pract Oncol; 2023 Sep; 14(6):503-518. PubMed ID: 37808071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma.
    Pozzi S; Bari A; Pecherstorfer M; Vallet S
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Belantamab mafodotin for the treatment of multiple myeloma.
    Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
    Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
    Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
    Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
    Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semi-automation of keratopathy visual acuity grading of corneal events in belantamab mafodotin clinical trials: clinical decision support software.
    Talekar MK; Painter JL; Elizalde MA; Thomas M; Stein HK
    Front Digit Health; 2023; 5():1138453. PubMed ID: 37881364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
    Condorelli A; Garibaldi B; Gagliano C; Romano A; Del Fabro V; Parrinello NL; Longo A; Cosentino S; Di Raimondo F; Conticello C
    Acta Haematol; 2024; 147(4):493-498. PubMed ID: 34839282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Belantamab mafodotin associated corneal microcyst-like epithelial changes.
    Chuang K; Pineda R; Liu S
    Am J Ophthalmol Case Rep; 2022 Mar; 25():101392. PubMed ID: 35198816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging.
    Mencucci R; Cennamo M; Alonzo L; Senni C; Vagge A; Ferro Desideri L; Scorcia V; Giannaccare G
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35629012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Belantamab mafodotin for relapsed or refractory multiple myeloma.
    Gil-Sierra MD; Briceño-Casado MDP
    J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin.
    Lu R; Morphey A; Diaz F; Chen J; Razmandi A; Richards T
    J Adv Pract Oncol; 2023 May; 14(4):300-306. PubMed ID: 37313276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How I treat relapsed and/or refractory multiple myeloma.
    Lee HC; Cerchione C
    Hematol Rep; 2020 Sep; 12(Suppl 1):8955. PubMed ID: 33042504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report.
    Marquant K; Quinquenel A; Arndt C; Denoyer A
    J Hematol Oncol; 2021 Oct; 14(1):159. PubMed ID: 34602074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
    Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
    Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.